The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle

Wenwu Xiao, Yan Wang, Edmond Y. Lau, Juntao Luo, Nianhuan Yao, Changying Shi, Leah Meza, Harry Tseng, Yoshiko Maeda, Pappanaicken Kumaresan, Ruiwu Liu, Felice C. Lightstone, Yoshikazu Takada, Kit S. Lam

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The αvβ3 integrin, expressed on the surface of various normal and cancer cells, is involved in numerous physiologic processes such as angiogenesis, apoptosis, and bone resorption. Because this integrin plays a key role in angiogenesis and metastasis of human tumors, αvβ3 integrin ligands are of great interest to advances in targeted therapy and cancer imaging. In this report, one-bead one-compound (OBOC) combinatorial libraries containing the arginine-glycine-aspartic acid (RGD) motif were designed and screened against K562 myeloid leukemia cells that had been transfected with the human αvβ3 integrin gene. Cyclic peptide LXW7 was identified as a leading ligand with a built-in handle that binds specifically to αvβ3 and showed comparable binding affinity (IC50 = 0.68 ± 0.08 μmol/L) to some of the well-known RGD "head-to-tail" cyclic pentapeptide ligands reported in the literature. The biotinylated form of LXW7 ligand showed similar binding strength as LXW7 against αvβ3 integrin, whereas biotinylated RGD cyclopentapeptide ligands revealed a 2- to 8-fold weaker binding affinity than their free forms. LXW7 was able to bind to both U-87MG glioblastoma and A375M melanoma cell lines, both of which express high levels of αvβ3 integrin. In vivo and ex vivo optical imaging studies with the biotinylated ligand/streptavidin-Cy5.5 complex in nude mice bearing U-87MG or A375M xenografts revealed preferential uptake of biotinylated LXW7 in tumor. When compared with biotinylated RGD cyclopentapeptide ligands, biotinylated LXW7 showed higher tumor uptake but lower liver uptake.

Original languageEnglish
Pages (from-to)2714-2723
Number of pages10
JournalMolecular Cancer Therapeutics
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2010
Externally publishedYes

Fingerprint

Aspartic Acid
Integrins
Glycine
Arginine
Ligands
Technology
Neoplasms
Cyclic Peptides
Myeloid Leukemia
Streptavidin
K562 Cells
Optical Imaging
Myeloid Cells
Glioblastoma
Bone Resorption
Heterografts
Nude Mice
Inhibitory Concentration 50
Melanoma
Apoptosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. / Xiao, Wenwu; Wang, Yan; Lau, Edmond Y.; Luo, Juntao; Yao, Nianhuan; Shi, Changying; Meza, Leah; Tseng, Harry; Maeda, Yoshiko; Kumaresan, Pappanaicken; Liu, Ruiwu; Lightstone, Felice C.; Takada, Yoshikazu; Lam, Kit S.

In: Molecular Cancer Therapeutics, Vol. 9, No. 10, 10.2010, p. 2714-2723.

Research output: Contribution to journalArticle

Xiao, W, Wang, Y, Lau, EY, Luo, J, Yao, N, Shi, C, Meza, L, Tseng, H, Maeda, Y, Kumaresan, P, Liu, R, Lightstone, FC, Takada, Y & Lam, KS 2010, 'The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle', Molecular Cancer Therapeutics, vol. 9, no. 10, pp. 2714-2723. https://doi.org/10.1158/1535-7163.MCT-10-0308
Xiao, Wenwu ; Wang, Yan ; Lau, Edmond Y. ; Luo, Juntao ; Yao, Nianhuan ; Shi, Changying ; Meza, Leah ; Tseng, Harry ; Maeda, Yoshiko ; Kumaresan, Pappanaicken ; Liu, Ruiwu ; Lightstone, Felice C. ; Takada, Yoshikazu ; Lam, Kit S. / The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. In: Molecular Cancer Therapeutics. 2010 ; Vol. 9, No. 10. pp. 2714-2723.
@article{1b025e564a8a4753840c760956d59b23,
title = "The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle",
abstract = "The αvβ3 integrin, expressed on the surface of various normal and cancer cells, is involved in numerous physiologic processes such as angiogenesis, apoptosis, and bone resorption. Because this integrin plays a key role in angiogenesis and metastasis of human tumors, αvβ3 integrin ligands are of great interest to advances in targeted therapy and cancer imaging. In this report, one-bead one-compound (OBOC) combinatorial libraries containing the arginine-glycine-aspartic acid (RGD) motif were designed and screened against K562 myeloid leukemia cells that had been transfected with the human αvβ3 integrin gene. Cyclic peptide LXW7 was identified as a leading ligand with a built-in handle that binds specifically to αvβ3 and showed comparable binding affinity (IC50 = 0.68 ± 0.08 μmol/L) to some of the well-known RGD {"}head-to-tail{"} cyclic pentapeptide ligands reported in the literature. The biotinylated form of LXW7 ligand showed similar binding strength as LXW7 against αvβ3 integrin, whereas biotinylated RGD cyclopentapeptide ligands revealed a 2- to 8-fold weaker binding affinity than their free forms. LXW7 was able to bind to both U-87MG glioblastoma and A375M melanoma cell lines, both of which express high levels of αvβ3 integrin. In vivo and ex vivo optical imaging studies with the biotinylated ligand/streptavidin-Cy5.5 complex in nude mice bearing U-87MG or A375M xenografts revealed preferential uptake of biotinylated LXW7 in tumor. When compared with biotinylated RGD cyclopentapeptide ligands, biotinylated LXW7 showed higher tumor uptake but lower liver uptake.",
author = "Wenwu Xiao and Yan Wang and Lau, {Edmond Y.} and Juntao Luo and Nianhuan Yao and Changying Shi and Leah Meza and Harry Tseng and Yoshiko Maeda and Pappanaicken Kumaresan and Ruiwu Liu and Lightstone, {Felice C.} and Yoshikazu Takada and Lam, {Kit S.}",
year = "2010",
month = "10",
doi = "10.1158/1535-7163.MCT-10-0308",
language = "English",
volume = "9",
pages = "2714--2723",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle

AU - Xiao, Wenwu

AU - Wang, Yan

AU - Lau, Edmond Y.

AU - Luo, Juntao

AU - Yao, Nianhuan

AU - Shi, Changying

AU - Meza, Leah

AU - Tseng, Harry

AU - Maeda, Yoshiko

AU - Kumaresan, Pappanaicken

AU - Liu, Ruiwu

AU - Lightstone, Felice C.

AU - Takada, Yoshikazu

AU - Lam, Kit S.

PY - 2010/10

Y1 - 2010/10

N2 - The αvβ3 integrin, expressed on the surface of various normal and cancer cells, is involved in numerous physiologic processes such as angiogenesis, apoptosis, and bone resorption. Because this integrin plays a key role in angiogenesis and metastasis of human tumors, αvβ3 integrin ligands are of great interest to advances in targeted therapy and cancer imaging. In this report, one-bead one-compound (OBOC) combinatorial libraries containing the arginine-glycine-aspartic acid (RGD) motif were designed and screened against K562 myeloid leukemia cells that had been transfected with the human αvβ3 integrin gene. Cyclic peptide LXW7 was identified as a leading ligand with a built-in handle that binds specifically to αvβ3 and showed comparable binding affinity (IC50 = 0.68 ± 0.08 μmol/L) to some of the well-known RGD "head-to-tail" cyclic pentapeptide ligands reported in the literature. The biotinylated form of LXW7 ligand showed similar binding strength as LXW7 against αvβ3 integrin, whereas biotinylated RGD cyclopentapeptide ligands revealed a 2- to 8-fold weaker binding affinity than their free forms. LXW7 was able to bind to both U-87MG glioblastoma and A375M melanoma cell lines, both of which express high levels of αvβ3 integrin. In vivo and ex vivo optical imaging studies with the biotinylated ligand/streptavidin-Cy5.5 complex in nude mice bearing U-87MG or A375M xenografts revealed preferential uptake of biotinylated LXW7 in tumor. When compared with biotinylated RGD cyclopentapeptide ligands, biotinylated LXW7 showed higher tumor uptake but lower liver uptake.

AB - The αvβ3 integrin, expressed on the surface of various normal and cancer cells, is involved in numerous physiologic processes such as angiogenesis, apoptosis, and bone resorption. Because this integrin plays a key role in angiogenesis and metastasis of human tumors, αvβ3 integrin ligands are of great interest to advances in targeted therapy and cancer imaging. In this report, one-bead one-compound (OBOC) combinatorial libraries containing the arginine-glycine-aspartic acid (RGD) motif were designed and screened against K562 myeloid leukemia cells that had been transfected with the human αvβ3 integrin gene. Cyclic peptide LXW7 was identified as a leading ligand with a built-in handle that binds specifically to αvβ3 and showed comparable binding affinity (IC50 = 0.68 ± 0.08 μmol/L) to some of the well-known RGD "head-to-tail" cyclic pentapeptide ligands reported in the literature. The biotinylated form of LXW7 ligand showed similar binding strength as LXW7 against αvβ3 integrin, whereas biotinylated RGD cyclopentapeptide ligands revealed a 2- to 8-fold weaker binding affinity than their free forms. LXW7 was able to bind to both U-87MG glioblastoma and A375M melanoma cell lines, both of which express high levels of αvβ3 integrin. In vivo and ex vivo optical imaging studies with the biotinylated ligand/streptavidin-Cy5.5 complex in nude mice bearing U-87MG or A375M xenografts revealed preferential uptake of biotinylated LXW7 in tumor. When compared with biotinylated RGD cyclopentapeptide ligands, biotinylated LXW7 showed higher tumor uptake but lower liver uptake.

UR - http://www.scopus.com/inward/record.url?scp=77958059698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958059698&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-10-0308

DO - 10.1158/1535-7163.MCT-10-0308

M3 - Article

VL - 9

SP - 2714

EP - 2723

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 10

ER -